Literature DB >> 8665020

Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature.

M Hendrikx1, J Van Dorpe, W Flameng, W Daenen.   

Abstract

A case of aortic and mitral valve disease associated with ergotamine abuse is reported. A 34-year-old woman presented with dyspnea after a long standing history of peripheral vascular pathology associated with ergotamine abuse. Cardiac dysfunction was rapidly progressive. At surgery, nodular thickening of both valves and fusion of the posterior leaflet of the mitral valve were seen. Microscopy revealed proliferation of myofibroblasts with little destruction of normal valvular elements. The similarity to lesions in carcinoid heart disease and in methysergide-associated valvular disease suggests direct stimulation of myofibroblast growth by serotonin agonist effect.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8665020

Source DB:  PubMed          Journal:  J Heart Valve Dis        ISSN: 0966-8519


  8 in total

Review 1.  Appetite suppressants, cardiac valve disease and combination pharmacotherapy.

Authors:  Richard B Rothman; Michael H Baumann
Journal:  Am J Ther       Date:  2009 Jul-Aug       Impact factor: 2.688

Review 2.  Cellular mechanisms in mitral valve disease.

Authors:  Kareem Salhiyyah; Magdi H Yacoub; Adrian H Chester
Journal:  J Cardiovasc Transl Res       Date:  2011-09-03       Impact factor: 4.132

3.  A patient with four artificial heart valves after ergotamine therapy.

Authors:  M Bijl; T W Galema; L A van Herwerden; M J M Kofflard; P N W M Breuls; R B A van de Brink
Journal:  Neth Heart J       Date:  2006-12       Impact factor: 2.380

Review 4.  The promises and perils of psychedelic pharmacology for psychiatry.

Authors:  Tristan D McClure-Begley; Bryan L Roth
Journal:  Nat Rev Drug Discov       Date:  2022-03-17       Impact factor: 84.694

Review 5.  Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review.

Authors:  Malcolm Steiger; W Jost; F Grandas; G Van Camp
Journal:  J Neural Transm (Vienna)       Date:  2009-01-14       Impact factor: 3.575

Review 6.  Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction.

Authors:  Richard B Rothman; Bruce E Blough; Michael H Baumann
Journal:  Exp Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.157

7.  Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA).

Authors:  Michael H Baumann; Richard B Rothman
Journal:  Int Rev Neurobiol       Date:  2009       Impact factor: 3.230

Review 8.  Serotonergic drugs and valvular heart disease.

Authors:  Richard B Rothman; Michael H Baumann
Journal:  Expert Opin Drug Saf       Date:  2009-05       Impact factor: 4.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.